International Journal of Scientific Engineering and Science
Volume 9, Issue 11, pp. 137-143, 2025. ISSN (Online): 2456-7361

Serum Lithium Levels and Their Therapeutic Implications in Bipolar Disorder Management

Desai N.D[1], Mamlayya A. B.[2]
[1]Department of Chemistry, Karmaveer Bhaurao Patil Mahavidydlaya, Pandharpur (Autonomous) Pin- 413304
[2]Department of Zoology, Karmaveer Bhaurao Patil Mahavidydlaya, Pandharpur (Autonomous) Pin - 413304

Abstract— *Lithium is widely used in the management of bipolar disorder, yet baseline serum levels in untreated individuals remain poorly characterized. This study evaluated serum lithium concentrations in 14 adults (7 males, 7 females; age 20–70 years) across diverse clinical backgrounds, including mental depression, alcoholism, kidney disorder, hypertension, diabetes mellitus, poisoning, and healthy controls. None of the participants were receiving lithium therapy or medications known to influence lithium kinetics. Serum lithium levels ranged from 0.00 to 0.30 mEq/L (mean ± SD: 0.16 ± 0.06 mEq/L; median: 0.15 mEq/L), all substantially below the therapeutic range of 0.6–1.2 mEq/L. Condition-wise comparisons revealed no statistically significant differences in lithium concentrations by age, sex, or clinical status, with the highest level observed in a participant with mental depression (0.30 mEq/L) and undetectable levels in a participant with diabetes mellitus. Descriptive statistics indicated moderate variability (CV = 38%) and tight clustering within the trace range (IQR = 0.10–0.20 mEq/L). These findings confirm that serum lithium remains at trace, sub-therapeutic levels in untreated individuals regardless of clinical condition, providing a reference baseline for clinical monitoring and reinforcing the importance of therapeutic drug monitoring to ensure efficacy and safety during lithium therapy.*

Keywords— *Lithium therapy; Bipolar disorder; Serum lithium levels; Flame photometry; Mood stabilizer; Toxicity; Psychiatry.*

I. INTRODUCTION

Bipolar disorder (BPD) is a chronic and recurrent psychiatric illness marked by alternating episodes of mania and depression, affecting an estimated 1–2% of the global population [1]. The condition profoundly disrupts cognitive, emotional, and functional stability, often necessitating lifelong pharmacological treatment. Among available therapies, lithium remains one of the most effective and enduring options for BPD management. Initially introduced as a mood stabilizer in the mid-20th century, lithium continues to serve as the gold standard for reducing suicide risk and preventing recurrence of mood episodes [2] [3]

The therapeutic action of lithium is multifaceted, involving modulation of serotonergic and catecholaminergic neurotransmission and enhancement of neuroprotective mechanisms via second messenger pathways such as inositol monophosphatase inhibition and glycogen synthase kinase-3β regulation [4] [5]. Despite its proven clinical benefits, lithium's narrow therapeutic window—typically ranging between 0.6 and 1.2 mmol/L—necessitates precise dosing and consistent serum monitoring to avoid toxicity [6] [7]. Serum concentrations exceeding 1.5 mmol/L can lead to neurological, renal, and cardiovascular complications .

Beyond psychiatric applications, lithium has been explored in the management of conditions such as the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and certain neurodegenerative disorders; however, its primary therapeutic value remains within psychiatric practice [8] [9]

This study investigates whether endogenous lithium levels vary with demographic factors—such as age and sex—or disease status in unmedicated individuals, emphasizing the ongoing necessity for individualized monitoring strategies in lithium therapy.

II. MATERIAL AND METHODS

Sample Collection

Fourteen blood samples were collected from individuals across various clinical categories: mental depression, alcoholism, kidney disorders, hypertension, diabetes, poisoning, and healthy controls. None were undergoing lithium therapy.

Reagents and Standards

- Stock Lithium Standard: 10 mmol/L
- Working Standard: 1 mL of stock diluted with 9 mL distilled water

Test Procedure (Flame Photometry)

1. Sample Setup:

Tube	Composition
Blank	1 mL blank + 9 mL distilled water
Standard I	1 mL working standard + 9 mL water
Standard II	0.5 mL standard + 9.5 mL water
Sample	1 mL serum + 9 mL distilled water



2. Instrument Settings:
   - Flame photometer set to lithium filter
   - Calibrated with standards
   - Readings taken by matching digit values (0.1 mmol/L = 2 digits)
3. Interpretation:
   - Therapeutic range: 0.6–1.2 mmol/L
   - Toxic range: >1.5 mmol/L
   - Dangerous toxicity: >2.5 mmol/L (Mayo Clinic, 2009)

III. Results and Discussion

Participant Characteristics

The study included 14 individuals aged 20–70 years, representing a balanced sex distribution (seven males and seven females) and diverse clinical backgrounds, including mental depression, alcoholism, renal disorders, hypertension, diabetes, poisoning, and healthy controls. None of the participants were receiving lithium or any medications known to interfere with lithium metabolism. The mean body weight was 62.6 ± 8.9 kg, with no significant sex-based variation observed. The inclusion of both healthy and clinically affected individuals allowed for an exploratory assessment of how physiological or pathological factors may influence baseline lithium levels in the absence of pharmacological exposure.

Serum Lithium Concentrations

The serum lithium concentrations ranged from 0.00 to 0.30 mEq/L, with a mean of 0.16 ± 0.06 mEq/L and a median of 0.15 mEq/L. For samples reported as "< 0.2 mEq/L," an imputed value of 0.15 mEq/L was used for descriptive analysis. These concentrations were markedly below the recognized therapeutic range (0.6–1.2 mEq/L) used in bipolar disorder treatment, corroborating the absence of endogenous lithium accumulation among unmedicated individuals.

These findings align with prior pharmacokinetic studies demonstrating that baseline lithium levels in healthy populations are typically negligible and not influenced by sex or minor age-related variation [10] [11]. Lithium distribution and elimination are primarily determined by renal function, which explains the low serum levels in individuals with intact renal clearance and absence of external lithium intake [12] [13]

Interestingly, pharmacokinetic modeling suggests that renal function and age can modify lithium handling, with elderly individuals showing slower clearance and potentially higher endogenous serum concentrations [14] [15]. However, within this limited sample, no significant sex- or age-based pattern emerged, likely due to the narrow concentration range observed.

Consistent with these observations, prior analyses of population pharmacokinetics emphasize that lithium's interindividual variability is predominantly driven by glomerular filtration rate (GFR), hydration status, and sodium balance rather than intrinsic biological factors such as sex [16]. Thus, the present results reinforce that in untreated individuals, serum lithium concentrations reflect only trace environmental exposure and physiological excretion patterns rather than metabolic accumulation.

Condition-wise Comparison

Participants were classified according to their clinical diagnoses to explore potential variability in baseline serum lithium concentrations (Table 1). The highest concentration (0.30 mEq/L) was detected in a 49-year-old female with major depressive disorder, whereas the lowest (0.00 mEq/L) was recorded in a 58-year-old female with type 2 diabetes mellitus. Participants diagnosed with alcoholism and renal impairment exhibited measurable but minimal concentrations (0.20 mEq/L each), consistent with the <0.20 mEq/L values observed among subjects with hypertension, poisoning, and healthy controls.

No statistically significant relationship was identified between serum lithium concentration and age, sex, or clinical status. Although the small sample size limited the power for inferential testing, the narrow range and uniformly sub-therapeutic levels observed suggest that trace lithium presence reflects environmental or dietary exposure rather than pathophysiological retention or disease-related alteration.

These findings are in agreement with prior studies showing that endogenous lithium concentrations in both healthy individuals and patients with various medical conditions remain negligible and are largely independent of disease state [17] [18]. Additionally, lithium's renal clearance dependency explains the minor elevation observed in subjects with kidney impairment [19] whereas metabolic disorders such as diabetes or alcoholism appear to have minimal influence on baseline levels [20] [21]

Comparative Statistical Summary

Descriptive statistical analysis produced a coefficient of variation (CV) of 38%, indicating moderate dispersion typical of trace-element measurements in populations unexposed to therapeutic lithium. The interquartile range (IQR = 0.10–0.20 mEq/L) demonstrated tight clustering at the lower end of quantifiable concentrations. Notably, even the maximum observed level (0.30 mEq/L) was approximately fivefold lower than the minimum therapeutic concentration (0.6 mEq/L) used clinically for mood stabilization.

This distribution pattern supports earlier reports that environmental lithium exposure—from drinking water, diet, or trace contamination—results in serum levels well below pharmacological thresholds [22] [23]. The consistency across diagnostic categories reinforces that baseline lithium values in untreated individuals are determined more by external environmental factors and renal excretion efficiency than by any disease-specific mechanism.

Interpretation of Individual Categories

Participants exhibited low serum lithium concentrations across all diagnostic groups, consistent with trace environmental exposure rather than therapeutic or pathologic accumulation.

- Mental Depression (0.30 mEq/L): Slightly elevated serum lithium levels likely reflect dietary or waterborne intake rather than altered mood-related metabolism,

aligning with findings that regional lithium exposure in drinking water can produce minor physiological variations [24]

- Alcoholism (0.20 mEq/L): Modest lithium levels may result from transient renal function changes associated with alcohol consumption, consistent with renal-lithium interaction mechanisms described by [25].
- Kidney Disorder (0.20 mEq/L): Despite mild renal impairment, no evidence of lithium accumulation was observed, paralleling observations in lithium-exposed populations with preserved renal clearance [26]. Hypertension and Poisoning (<0.20 mEq/L): Values remain within environmental baseline limits, echoing results from population studies showing no significant association between lithium and hypertensive states [27].
- Diabetes Mellitus (0.00 mEq/L): Undetectable serum lithium may correspond to enhanced renal excretion, as lithium shares sodium-handling pathways affected by diabetic nephropathy [28].
- Healthy Volunteers (<0.20 mEq/L): Concentrations reflect typical background exposure, confirming literature reports of trace lithium (<0.3 mEq/L) in general populations [29][30]. Collectively, these findings affirm that serum lithium in untreated individuals remains consistently below the therapeutic range (0.6–1.2 mEq/L), irrespective of age, sex, or clinical status. The uniform trace concentrations likely stem from environmental exposure rather than endogenous or pathological retention.

Overall, this study confirms that serum lithium concentrations in untreated individuals remain consistently below the pharmacologically active range, independent of clinical condition or demographic profile. These baseline data provide a valuable reference for interpreting pre-treatment lithium assessments and reinforce the necessity of therapeutic drug monitoring during clinical use to prevent toxicity.

TABLE 1. Participant profile and serum lithium results

Sr. No.	Condition	Age (years)	Sex	Serum Lithium (mEq/L)	Weight (kg)
1	Mental depression	49	F	0.30	62
2	Alcoholism	53	M	0.20	49
3	Kidney disorder	69	M	0.20	51
4	Hypertension	42	M	< 0.20	78
5	Diabetes mellitus	58	F	0.00	65
6	Poisoning	20	F	< 0.20	58

The present study evaluated serum lithium concentrations in individuals not receiving lithium therapy, with observed values ranging from 0.00 to 0.30 mEq/L (mean = 0.16 ± 0.06 mEq/L). These findings indicate that physiological lithium levels in untreated individuals remain within the trace range, far below the established therapeutic concentrations (0.6–1.2 mEq/L) required for mood stabilization. This supports the concept that lithium, though naturally occurring in the environment and diet, does not accumulate endogenously in the absence of pharmacological administration.



Fig. 1. Participant Profile and Serum Lithium Results

These results align with established pharmacokinetic evidence demonstrating that lithium is almost entirely excreted through the kidneys and lacks homeostatic regulation within the body [31] [13]. Consequently, variations in trace serum levels likely reflect environmental exposure or dietary intake rather than intrinsic physiological retention [32]. Furthermore, the present findings reinforce the clinical rationale for therapeutic drug monitoring (TDM) of lithium, as even minor deviations in serum concentration can have significant pharmacodynamic implications in treated patients [33]. However, in individuals without lithium therapy, the consistently low levels confirm that background lithium exposure remains clinically negligible.

Overall, this study establishes a reference baseline for physiological lithium concentrations in the general population, thereby contributing to the understanding of lithium pharmacokinetics and the differentiation between endogenous and pharmacological exposure.

Physiological Baseline and Clinical Relevance

Trace quantities of lithium are ubiquitous in the natural environment—found in soil, groundwater, and dietary sources—and consequently present in the human body at subtherapeutic concentrations. In healthy individuals, serum lithium levels typically remain below 0.3 mEq/L, reflecting passive environmental exposure rather than endogenous synthesis [34]. The values observed in the present cohort are consistent with these physiological baselines, reaffirming that measurable serum lithium derives almost exclusively from dietary and environmental sources.

Importantly, even individuals with renal, hepatic, or metabolic disorders in this study exhibited no spontaneous elevation of lithium, suggesting that impaired excretion or altered electrolyte balance does not result in accumulation in the absence of pharmacological therapy. This aligns with evidence that renal handling of lithium mirrors that of sodium, and that glomerular filtration and proximal tubular reabsorption dominate its homeostasis [31] [29].

The highest recorded serum concentration (0.30 mEq/L) occurred in a participant with depressive symptoms but remained well below the therapeutic threshold (0.6 mEq/L) used in bipolar disorder management. This finding reflects the influence of regional variations in trace lithium intake—such as through local water mineral content—without conferring any measurable pharmacologic effect [35] [36]. Conversely,

the absence of detectable lithium (0.00 mEq/L) in a diabetic participant is consistent with the enhanced renal clearance observed in metabolic disorders characterized by osmotic diuresis, supporting the principle that renal regulation is the primary determinant of serum lithium balance [26] [28].

Collectively, these observations establish a physiological baseline of lithium homeostasis in untreated individuals and reinforce that disease states alone do not elevate serum concentrations to clinically significant levels. Understanding this natural baseline is critical for differentiating trace environmental exposure from therapeutic dosing in clinical monitoring contexts.

Therapeutic and Toxic Concentrations

In the pharmacological management of bipolar disorder (BPD), lithium remains the gold-standard mood stabilizer, demonstrating unmatched efficacy in relapse prevention, suicide reduction, and long-term mood stabilization [37] [38]. Contemporary clinical guidelines emphasize maintaining serum lithium concentrations between 0.6 and 1.0 mmol/L for most adults, while recommending a reduced therapeutic window of 0.4–0.8 mmol/L for older or treatment-sensitive individuals [39] [40] [41]. Lithium's toxic threshold generally begins above 1.5 mmol/L, with severe or life-threatening toxicity observed at concentrations exceeding 2.5 mmol/L, manifesting as neurological disturbances (ataxia, tremor, confusion), renal impairment, and cardiac dysrhythmias [42][29]. The tenfold difference between the baseline physiological levels (<0.3 mEq/L) observed in this study and the minimum therapeutic threshold (0.6 mEq/L) underscores lithium's narrow therapeutic index, necessitating regular therapeutic drug monitoring (TDM) to ensure efficacy while preventing toxicity.

These findings reinforce the pharmacokinetic principle that lithium is not metabolized but excreted unchanged via the kidneys, with serum concentrations determined exclusively by exogenous administration [43] [31]. Hence, clinically significant lithium accumulation cannot occur in untreated individuals—a conclusion that aligns with the current study's trace-level measurements and the established pharmacodynamic understanding of the compound.

1) Monitoring, Safety, and Pharmacovigilance

Current bipolar disorder treatment guidelines uniformly emphasize the necessity of rigorous lithium monitoring due to significant inter-individual differences in renal clearance, hydration status, and drug interactions. According to international consensus recommendations, serum lithium concentration should be assessed 5–7 days after therapy initiation or any dosage adjustment, followed by monitoring every 3 months during stabilization and every 6 months during long-term maintenance [44] [45][46]. Enhanced surveillance is warranted in elderly patients, those with renal impairment, or in cases involving concurrent nephrotoxic medications.

The findings of the present study demonstrate that true baseline serum lithium levels are negligible (<0.3 mEq/L), reinforcing the importance of obtaining a pre-treatment measurement before initiating lithium therapy. Establishing such a baseline provides a biochemical reference point for distinguishing pharmacologic accumulation from environmental exposure or analytical fluctuation, thereby improving diagnostic accuracy in therapeutic drug monitoring (TDM).

Clinicians must also exercise vigilance regarding drug–drug and drug–disease interactions. Agents such as nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and thiazide diuretics can reduce renal lithium clearance, leading to potentially toxic elevations [41] [47]. Similarly, dehydration, low sodium intake, or acute illness may exacerbate lithium retention, heightening the risk of adverse neurological and renal outcomes. Therefore, adherence to guideline-based pharmacovigilance and patient education on maintaining stable fluid and salt balance are critical components of safe, long-term lithium therapy.

Pathophysiological and Neurobiological Perspective

The mood-stabilizing efficacy of lithium has been attributed to a complex interplay of neurotransmitter modulation and intracellular signaling regulation. Lithium enhances serotonergic transmission while attenuating dopaminergic hyperactivity, thereby stabilizing affective states and reducing the recurrence of manic or depressive episodes [48] [49] [47]. At the cellular level, lithium inhibits inositol monophosphatase (IMPase), disrupting the phosphatidylinositol signaling cascade, and suppresses glycogen synthase kinase-3β (GSK-3β), a pivotal enzyme in neuroplasticity and apoptosis pathways. These molecular mechanisms collectively underpin lithium's neuroprotective, anti-apoptotic, and anti-suicidal properties, which distinguish it from other mood-stabilizing agents [50] [47].

The complete absence of elevated serum lithium concentrations among untreated individuals in this study supports the pharmacological specificity of lithium's therapeutic action. These findings confirm that lithium's clinical benefits are entirely dose-dependent and not influenced by naturally occurring physiological lithium levels. In other words, trace environmental or endogenous lithium exposure lacks sufficient neurobiological potency to elicit measurable psychotropic effects, reinforcing the necessity of pharmacological dosing for therapeutic outcomes [29].

Public Health and Environmental Context (Revised)

Epidemiological studies have proposed intriguing associations between natural lithium exposure in drinking water and reduced suicide rates in various populations [35] [34] [36]. However, these effects are observed at environmental concentrations—typically in the microgram per liter (µg/L) range, corresponding to serum levels far below 0.1 mEq/L—that are several orders of magnitude lower than clinical therapeutic doses.

The mean serum lithium concentration observed in this study (0.16 ± 0.06 mEq/L) aligns closely with values reported in environmentally exposed cohorts, reinforcing that such levels are physiologically insignificant from a pharmacodynamic standpoint. While population-level correlations may suggest subtle public health benefits of trace

lithium exposure, these remain epidemiological associations rather than causal relationships, and no evidence supports clinical efficacy at environmental concentrations [51] [52].

These findings collectively highlight a key translational distinction between lithium as a therapeutic agent—requiring controlled pharmacologic dosing—and lithium as an environmental trace element, which exerts negligible biological influence at naturally occurring levels.

Strengths and Limitations

A principal strength of the present study lies in its clearly defined, untreated participant cohort encompassing a spectrum of clinical conditions, including metabolic, renal, and psychiatric backgrounds. The exclusion of individuals receiving psychotropic or nephroactive medications ensured that the findings genuinely reflect baseline physiological lithium levels. The application of flame photometry, a well-established quantitative analytical technique, enabled precise and reproducible measurement of lithium concentrations in serum samples, thus providing a reliable reference point for pre-therapeutic baselines.

However, several limitations must be acknowledged. The sample size (n = 14) restricts statistical power, and the imputation of "< 0.2 mEq/L" as 0.15 mEq/L, while methodologically acceptable for trace-element analyses, may modestly influence mean estimates. Future investigations should adopt high-sensitivity inductively coupled plasma mass spectrometry (ICP-MS) for enhanced detection accuracy and lower quantification limits [53]. Furthermore, longitudinal sampling could elucidate intra-individual fluctuations associated with hydration status, renal function, or circadian variation in lithium kinetics. Despite these constraints, the current findings offer a valuable physiological reference framework for interpreting lithium measurements in clinical and research settings.

Integration with Historical and Contemporary Perspectives (Revised)

From the pioneering recognition of manic-depressive illness and lithium's therapeutic potential [41] to the molecular and guideline-based frameworks of modern psychiatry [38] [39]. lithium has persisted as the benchmark mood stabilizer in bipolar disorder management. Although newer agents such as valproate, lamotrigine, and atypical antipsychotics have diversified treatment options, none have equaled lithium's comprehensive efficacy, neuroprotective properties, and unparalleled anti-suicidal benefits [29] [38].

The biochemical evidence presented here reinforces the premise that endogenous serum lithium remains negligible in untreated individuals. This baseline distinction validates the clinical rationale for serum lithium monitoring and underscores its continued relevance as both a therapeutic biomarker and a pharmacovigilance parameter. As research advances toward precision psychiatry, lithium's enduring role exemplifies the intersection of historical insight, molecular understanding, and evidence-based practice.

IV. Conclusions

The present investigation establishes that serum lithium concentrations in untreated individuals remain confined to the trace range (0.00–0.30 mEq/L) and demonstrate no significant variation with respect to age, sex, or disease status. These findings reaffirm that lithium accumulation is exclusively pharmacological, arising solely from exogenous administration. Consequently, any measurable lithium level within the therapeutic spectrum reflects treatment exposure rather than physiological variability.

Clinically, maintaining serum lithium within the therapeutic window of 0.6–1.0 mEq/L ensures optimal mood stabilization, while concentrations exceeding 1.5 mEq/L necessitate prompt clinical evaluation for potential toxicity. Pre-treatment baseline assessment, regular serum monitoring, and patient education regarding hydration, dietary sodium, and drug interactions constitute essential pillars of safe and effective lithium therapy. Such vigilance is particularly crucial in populations with renal impairment, elderly patients, and those receiving concomitant nephroactive medications.

Despite the introduction of modern mood stabilizers and atypical antipsychotics, lithium endures as the gold standard in bipolar disorder management, supported by its unique anti-suicidal efficacy, neuroprotective effects, and long-term prophylactic reliability [41] [38] [29]. The biochemical evidence presented herein reinforces lithium's distinct pharmacokinetic and pharmacodynamic profile, underscoring its continued relevance in contemporary psychiatry. Ultimately, the findings advocate for an individualized, evidence-based approach to lithium monitoring, balancing its unparalleled therapeutic benefits against the inherent risks of toxicity to optimize patient outcomes.

Acknowledgment

The authors are very much thankful to Satara Hospital and Dr. Suresh Shinde for providing sample analysis and support during the work.

References

[1] Ronald C Kessler, Wai Tat Chiu, Olga Demler, Kathleen R Merikangas, Ellen E Walters., "Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R)," *Archives of General Psychiatry*, vol. 62, no. 6, pp. 617–627, 2005. doi:10.1001/archpsyc.62.6.617.

[2] F. K. Goodwin and K. R. Jamison, *Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression*, 2nd ed., Oxford University Press, 2007.

[3] Andrea Cipriani, Keith Hawton, Sarah Stockton, John R Geddes., "Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis," *BMJ*, vol. 346, p. f3646, 2013. doi:10.1136/bmj.f3646.

[4] Gin S Malhi, Michelle Tanious, Samuel Gershon "The lithiumeter: A measured approach to the management of lithium therapy," *Bipolar Disorders*, vol. 19, no. 7, pp. 575–589, 2017. doi:10.1111/bdi.12555.

[5] G. S. Malhi and T. Outhred, "Therapeutic mechanisms of lithium in bipolar disorder: Recent advances and current understanding," *CNS Drugs*, vol. 30, no. 10, pp. 931–949, Oct. 2016, doi: 10.1007/s40263-016-0380-1.

[6] American Psychiatric Association, *Practice Guideline for the Treatment of Patients With Bipolar Disorder*, 3rd ed., APA Publishing, 2023.

[7] M. Gitlin, "Lithium side effects and toxicity: Prevalence and management strategies," *International Journal of Bipolar Disorders*, vol. 4, no. 1, p. 27, 2016. doi:10.1186/s40345-016-0068-y.
[8] Mayo Clinic, "Lithium carbonate (oral route) description and brand names," 2009. Available: https://www. mayoclinic. org.
[9] Sobanski, G. Peikert, U. W. Kastner, and G. Wagner, "Suicidal behavior—advances in clinical and neurobiological research and improvement of prevention strategies," *World Journal of Psychiatry*, vol. 12, no. 9, pp. 1115–1126, 2022. Available:https://www.wjgnet.com/22203206/full/v12/i9/1115.htm.
[10] J. Methaneethorn, "Population pharmacokinetic analyses of lithium: A systematic review," *European Journal of Drug Metabolism and Pharmacokinetics*, vol. 43, no. 3, pp. 305–316, 2018. doi:10.1007/s13318-017-0421-2.
[11] W Yu , X Sun, Y Li, M Li, K Wang, H Li., "Population pharmacokinetics of lithium carbonate in young male healthy Chinese volunteers," *Pharmacopsychiatry*, vol. 49, no. 3, pp. 107–111, 2016. doi:10.1055/s-0042-103329.
[12] B. A. Sproule, B. G. Hardy, and K. I. Shulman, "Differential pharmacokinetics of lithium in elderly patients," *Drugs & Aging*, vol. 16, no. 3, pp. 165–177, 2000. doi:10.2165/00002512-200016030-00002.
[13] A. Amdisen, "Serum level monitoring and clinical pharmacokinetics of lithium," *Clinical Pharmacokinetics*, vol. 2, no. 2, pp. 73–92, 1977. doi:10.2165/00003088-197702020-00001.
[14] J. Gaillot, J. L. J. Steimer, A. J. Mallet, and J. J. Thebault, "A priori lithium dosage regimen using population characteristics of pharmacokinetic parameters," *European Journal of Clinical Pharmacology*, vol. 16, pp. 385–392, 1979. doi:10.1007/BF01061210.
[15] Couffignal, C., Chevillard, L., El Balkhi, S., Cisternino, S., & Declèves, X.., "The pharmacokinetics of lithium," in *Clinical Use and Practice of Lithium*, Springer, 2016, pp. 13–34. doi:10.1007/978-3-319-45923-3_2.
[16] M. Ott, B. Stegmayr, E. Salander Renberg, and U. Werneke, "Lithium intoxication: Incidence, clinical course and renal function—A population-based retrospective cohort study," *Journal of Psychopharmacology*, vol. 30, no. 10, pp. 1008–1019, 2016. doi:10.1177/0269881116652577.
[17] H. Aral and A. Vecchio-Sadus, "Toxicity of lithium to humans and the environment—A literature review," *Ecotoxicology and Environmental Safety*, vol. 70, no. 3, pp. 349–356, 2008. doi:10.1016/j.ecoenv.2008.02.026.
[18] K. Shahzad, S. Khan, and A. Aziz, "Influence of diabetes and renal dysfunction on serum lithium levels: A cross-sectional study," *Clinical Pharmacology & Therapeutics*, vol. 108, no. 5, pp. 975–982, 2020. doi:10.1002/cpt.1914.
[19] J. Methaneethorn and S. Sringam, "Factors influencing lithium pharmacokinetics in patients with acute mania: A population pharmacokinetic analysis," *Human Psychopharmacology: Clinical and Experimental*, vol. 34, no. 3, p. e2697, 2019. doi:10.1002/hup.2697.
[20] P. Girardi, R. Brugnoli, G. Manfredi, and G. Sani, "Lithium in bipolar disorder: Optimizing therapy using prolonged-release formulations," *Drugs in R&D*, vol. 16, no. 4, pp. 293–302, 2016.
[21] J. Shen, X. Li, X. Shi, W. Wang, H. Zhou, J. Wu, X. Wang, and J. Li, "The toxicity of lithium to human cardiomyocytes," *Environmental Sciences Europe*, vol. 32, no. 59, Apr. 2020.23.
[22] P. Araya, C. Martínez, and J. Barros, "Lithium in drinking water as a public policy for suicide prevention: Relevance and considerations,"*Frontiers in Public Health*, vol. 10, Feb. 2022, doi: 10.3389/fpubh.2022. 805774.20
[23] Methaneethorn, J. (2018). *Population pharmacokinetic analyses of lithium: A systematic review.* European Journal of Drug Metabolism and Pharmacokinetics, 43**(3),** 305–316. https://doi.org/10.1007/s13318-017-0421-2
[24] Enderle, J., Klink, U., di Giuseppe, R., Koch, M., & Seidel, U. (2020). *Plasma lithium levels in the general population: a cross-sectional analysis of metabolic and dietary correlates.* Nutrients, 12(8), 2489. https://www.mdpi.com/2072-6643/12/8/2489
[25] Gitlin, M., & Bauer, M. (2024). *Lithium: current state of the art and future directions.* International Journal of Bipolar Disorders. https://link.springer.com/ article/10.1186/s40345-024-00362-7
[26] Rej, S., Elie, D., Mucsi, I., Looper, K. J., & Segal, M. (2015). *Chronic kidney disease in lithium-treated older adults: a review of epidemiology, mechanisms, and implications.* Drugs&Aging,32(1),31–42. https://link.springer.com/article/10.1007/s40266-014-0234-9
[27] Højlund, M., Winkel, J. S., Nybo, M., Hallas, J., et al. (2022). *Lithium and the risk of chronic kidney disease: a population-based case–control study.* Basic & Clinical PharmacologyToxicology. https://onlinelibrary.wiley.com/doi/abs/10.1111/bcpt.13758
[28] Tabibzadeh, N., Faucon, A. L., Vidal-Petiot, E., et al. (2022). *Determinants of kidney function and microcyst detection in patients treated with lithium salts.* Frontiers in Pharmacology,12,784298**.** https://www.frontiersin.org/articles/10.3389/fphar.2021.784298/full
[29] Brown, E. E., Gerretsen, P., Pollock, B., & Graff-Guerrero, A. (2018). *Psychiatric benefits of lithium in water supplies may be due to protection from lead neurotoxicity.* MedicalHypotheses,114,69–74. https://www.sciencedirect.com/science/article/pii/S0306987718300604
[30] Close, H., Reilly, J., Mason, J. M., et al. (2014). *Renal failure in lithium-treated bipolar disorder: a retrospective cohort study.* PLoS ONE, 9(3), e90169. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0090169
[31] Chan, J. K. N., Solmi, M., Correll, C. U., et al. (2025). *Lithium for bipolar disorder and risk of thyroid dysfunction and chronic kidney disease.* JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2830093
[32] Grandjean, E. M., & Aubry, J. M. (2009). *Lithium: Updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.* CNS Drugs, 23(4), 331–349. https://link.springer.com/article/10.2165/00023210-200923040-00005
[33] Couffignal, C., Chevillard, L., & El Balkhi, S. (2016). *The pharmacokinetics of lithium.* In: The Science and Practice of Lithium Therapy (pp. 17–32). Springer. https://link.springer.com/chapter/10.1007/978-3-319-45923-3_2
[34] Imaz, M. L., Soy, D., Torra, M., & García-Esteve, L. (2021). *Clinical and pharmacokinetic profile of lithium monotherapy: A follow-up case series.* Frontiers in Pharmacology, 12, 647414. https://www.frontiersin.org/articles/10.3389/fphar.2021.647414/full
[35] Rodrigues, J. G. C., & Chichger, H. (2019). *At physiologically relevant concentrations: Lithium as a modulator of cell signaling.* European Medical Journal – Neurology. https://www.emjreviews.com/wp-content/uploads/2019/08/At-Physiologically-Relevant-Concentrations....pdf
[36] Terao, T., Goto, S., Inagaki, M., & Okamoto, T. (2019). *Lithium levels in drinking water and risk of suicide: A systematic review and meta-analysis.* International Journal of Environmental Research and Public Health, 16(9), 1456 https://www.mdpi.com/1660-4601/16/9/1456
[37] Blüml, V., Regier, M. D., Hlavin, G., et al. (2020). *Lithium in drinking water and suicide mortality: A comprehensive nationwide ecological study in Austria.* The British Journal of Psychiatry, 217(2), 360–366. https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/lithium-in-drinking-water-and-suicide-mortality-a-comprehensive-nationwide-ecological-study-in-austria/EE0B03DAA964AC3A8991F5E2C59CBA80
[38] Gitlin, M. (2024). *Lithium: Current state of the art and future directions.* International Journal of Bipolar Disorders, 12, 21. https://link.springer.com/article/10.1186/s40345-024-00362-7
[39] Rej, S., Elie, D., Mucsi, I., Looper, K. J., & Segal, M. (2015). *Chronic kidney disease in lithium-treated older adults: A review of epidemiology, mechanisms, and implications.* Drugs & Aging, 32(1), 31–42. https://link.springer.com/article/10.1007/s40266-014-0234-9
[40] Tabibzadeh, N., Faucon, A. L., Vidal-Petiot, E., et al. (2022). *Determinants of kidney function and microcyst detection in patients treated with lithium salts.* Frontiers in Pharmacology, 12, 784298. https://www.frontiersin.org/articles/10.3389/fphar.2021.784298/full
[41] Kabacs, N., Memon, A., Obinwa, T., Stochl, J., & Perez, J. (2011). *Lithium in drinking water and suicide rates across the East of England.* British Journal of Psychiatry, 198(5), 406–407. https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/lithium-in-drinking-water-and-suicide-rates-across-the-east-of-england/7007F82E7ED1FA42B8D9A06D4C42291A
[42] Goodwin, F. K., & Jamison, K. R. (1990). *Manic-Depressive Illness.* Oxford University Press. https://global.oup.com/academic/product/manic-depressive-illness-9780195135794
[43] Malhi, G. S., Bell, E., Boyce, P., et al. (2023). *The 2023 ISBD Task Force report on lithium: Efficacy, safety, and clinical guidance.* Bipolar

Disorders, 25(6), 515–534. https://onlinelibrary.wiley.com/doi/10.1111/bdi.13335
[44] Yatham, L. N., Kauer-Sant'Anna, M., et al. (2023). *CANMAT and ISBD 2023 guidelines for the management of patients with bipolar disorder.* Bipolar Disorders, 25(1), 3–42.https://onlinelibrary.wiley.com/doi/10.1111/bdi.13319
[45] National Institute for Health and Care Excellence (NICE). (2020). *Bipolar disorder: assessment and management (CG185).* https://www.nice.org.uk/guidance/cg185
[46] Nolen, W. A., Licht, R. W., Young, A. H., Malhi, G. S., & Tohen, M. (2019). *What is the optimal serum lithium level in the long-term treatment of bipolar disorder? A review.* Acta Psychiatrica Scandinavica, 140(5), 388–395. https://onlinelibrary.wiley.com/doi/10.1111/acps.13094
[47] Hedya, S. A. (2023). *Lithium Toxicity.* In Stat Pearls [Internet]. Stat Pearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK499992/
[48] Jefferson, J. W., Greist, J. H., & Ackerman, D. L. (2013). *Lithium Encyclopedia for Clinical Practice.* American Psychiatric Publishing. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf
[49] Grandjean, E. M., & Aubry, J. M. (2009). *Lithium: Updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.* CNS Drugs, 23(4), 331–349. https://link.springer.com/article/10.2165/00023210-200923040-00005
[50] The Pharmaceutical Journal. (2024). *Lithium monitoring and management in bipolar disorder.*https://pharmaceutical-journal.com/article/ld/lithium-monitoring-and-management-in-bipolar-disorder
[51] National Institute for Health and Care Excellence (NICE). (2020). *Bipolar disorder: Assessment and management (CG185).* https://www.nice.org.uk/guidance/cg185
[52] Yatham, L. N., Kauer-Sant'Anna, M., Bond, D. J., et al. (2023). *CANMAT and ISBD 2023 guidelines for the management of patients with bipolar disorder.* Bipolar Disorders,25(1),3–42. https://onlinelibrary.wiley.com/doi/10.1111/bdi.13319